Mylan reaches agreement with Aspen for their European thrombosis business
pharmafile | September 8, 2020 | News story | Manufacturing and Production | Mylan, aspen
Mylan has announced an agreement to acquire the intellectual property and commercialisation rights to Aspen’s thrombosis business for €641.9 million.
This includes an upfront payment of €263.2 million and Mylan expects to pay the remainder of the deal from profits generated from their operations by 25 June 2021.
Mylan President Rajiv Malik commented on the deal: “The acquisition of this thrombosis portfolio is a significant addition to Mylan’s European business that will not only make Mylan the second largest supplier of these products to patients in Europe, according to IQVIA, but also bolster our existing commercial infrastructure to further expand access to complex injectables.
“By adding to our highly experienced sales and marketing team, we will further strengthen our current reach in hospitals and enhance the future growth of our biosimilars franchise in Europe.”
Aspen will still manufacture and supply Mylan with the product via their supply chain that is primarily located in Europe.
The portfolio of products acquired in the deal includes Arixtra, Fraxiparine, Mono-Embolix and Orgaran. Over the last year, this portfolio has generated €231 million in revenue.
Robert J Coury, Mylan’s Executive Chairman, said: “As we continue toward the launch of Viatris, we remain committed to executing on opportunities that will not only add to Mylan’s growth, but that also will be consistent with our vision for Viatris under the Global Healthcare Gateway, which we believe will establish the new company as a true partner of choice.”
Conor Kavanagh
Related Content
Pfizer to pay $345 million in EpiPen lawsuit
Pfizer has reached a $345 million settlement over consumer claims they overpaid for EpiPens as …
Mylan secures first FDA approval for generic version of Biogen’s Tecfidera following patent dispute
The FDA has approved its first generic of Biogen’s multiple sclerosis (MS) treatment Tecfidera, awarding …
Mylan launches generic version of Gilead’s remdesivir for COVID-19 patients in India
Mylan has launched its own generic version of Gilead’s remdesivir on the Indian market for …
